The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Chronic Kidney Diseases
In brief
The incidence of Chronic kidney disease (CKD) is showing an upward trend, but the therapeutic effect of treatment is limited. Remote ischemic conditioning (RIC) has the potential to safeguard remote organs via the repeated application of brief ischemic stimuli. the aim of our study is to investigate whether RIC can protect the renal function in patients with CKD.
Key facts
- Study ID
- NCT06501222
- Run by
- Yuanjun Yang
- People needed
- 114
- Starts
- 2024-03-01
- Expected to finish
- 2027-03-30
- Last updated by the study team
- 2024-08-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- CKD Patients with eGFR ≥ 15ml/min/1.73m2
- Age ≥ 18 years old
- 24-hour urine protein excretion ≤ 3.5g
- Subjects who have signed the informed consent form
You may not qualify if…
- Patients with nephrotic syndrome
- Patients with acute kidney injury
- Patients who have undergone renal replacement treatment in the past
- Patients who may have medication changes during RIC or sham-RIC intervention
- Patients with a history of diabetes or glycated hemoglobin > 8%
- Patients with familial hypercholesterolemia (>5.5 mmol/L) accompanied by high low-density lipoprotein (>2.5 mmol/L)
- Patients with contraindications to RIC, such as vascular injury, soft tissue injury, fracture, infection, or known peripheral vascular disease in both arms
- Patients with a history of hemostatic disorders, systemic bleeding, or thrombocytopenia
- Patients with cardiogenic embolism (atrial fibrillation) or other severe arrhythmias (severe bradycardia, third-degree atrioventricular block, or ventricular tachycardia), previous myocardial infarction, or severe heart failure (New York Heart Association Class III and IV)
- Uncontrolled hypertension (defined as systolic blood pressure ≥ 200 mmHg despite antihypertensive treatment)
- Patients with respiratory failure, malignant tumors, or other autoimmune diseases
- Women who are pregnant or breastfeeding at the time of enrollment or any time during the study
Where it is running
- chinese PLA general hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.